Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005).

BACKGROUND Sentinel lymph node biopsy (SLNB), an acceptable alternative to axillary lymph node dissection for staging patients with breast cancer, was introduced to clinical practice in the late 1990s. We assessed demographic, clinical, and facility-related factors associated with SLNB in women with early-stage breast cancer and evaluated trends in these factors over time. METHODS Data on early-stage breast cancers (T1a, T1b, T1c, and T2N0) diagnosed between January 1, 1998, and December 31, 2005, were extracted from the National Cancer Database, a hospital-based registry. Patient demographics, tumor stage, type of lymph node surgery, type of breast cancer surgery, health insurance, treatment facility type, and area-level education and income variables were collected. Multivariable logistic regression analyses were performed to assess predictive factors associated with SLNB, temporal differences in factors associated with SLNB, and differences in rates of SLNB by facility type, race/ethnicity, and type of health insurance over time. RESULTS The total analytic study population included 490,899 women. The use of SLNB increased from 26.8% in 1998 to 65.5% in 2005. Factors associated with lower likelihood of SLNB over the study period included being older (odds ratio [OR] = 0.80, 95% confidence interval [CI] = 0.78 to 0.92 for those aged 72 or older compared with those aged 51 or younger), being of racial/ethnic minority (OR = 0.76, 95% CI = 0.74 to 0.78 for African Americans compared with whites), having no health insurance (OR = 0.77, 95% CI = 0.73 to 0.80 for uninsured compared with having private insurance), having certain government insurance plans (for Medicaid, OR = 0.81, 95% CI = 0.78 to 0.84, and for Medicare at age <65 years, OR = 0.83, 95% CI = 0.80 to 0.87, both compared with private insurance), residing in zip codes with lower proportion of high school graduates (OR = 0.88, 95% CI = 0.86 to 0.89) or with lower median income (OR = 0.79, 95% CI = 0.77 to 0.81), and receiving treatment in facility types other than a teaching or research hospital (for community hospital, OR = 0.84, 95% CI = 0.82 to 0.86; for community cancer center, OR = 0.86, 95% CI = 0.84 to 0.87). The associations with insurance status and sociodemographic characteristics were more pronounced in 2005 than in 1998. For example, the adjusted annual rates of SLNB in 1998 were 0.29 in whites, 0.26 in African Americans, and 0.35 in Hispanics; in 2005 the respective rates were 0.70, 0.64, and 0.67. CONCLUSIONS Although use of SLNB increased from 1998 to 2005, disparities persisted in receipt of SLNB that are based on nonclinical factors, including sociodemographic characteristics and insurance status.

[1]  A. Y. de Kanter,et al.  5-Year follow-up of sentinel node negative breast cancer patients. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  P. Schlag,et al.  Long‐term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection , 2006, Journal of surgical oncology.

[3]  C. Laronga,et al.  Impact of Race on Breast Cancer in Lower Socioeconomic Status Women , 2006, The breast journal.

[4]  K. McMasters,et al.  Surgeon and community factors affecting breast cancer sentinel lymph node biopsy. , 2005, American journal of surgery.

[5]  J. Hentz,et al.  Older Age Independently Predicts a Lower Risk of Sentinel Lymph Node Metastasis in Breast Cancer , 2005, Annals of Surgical Oncology.

[6]  E. Winer,et al.  American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Giuliano,et al.  Sentinel Node Skills Verification and Surgeon Performance: Data From a Multicenter Clinical Trial for Early-Stage Breast Cancer , 2005, Annals of surgery.

[8]  J. Gardiner,et al.  Cancer, Medicaid enrollment, and survival disparities , 2005, Cancer.

[9]  R. Coates,et al.  Racial differences in diagnosis, treatment, and clinical delays in a population‐based study of patients with newly diagnosed breast carcinoma , 2004, Cancer.

[10]  P. Dijkstra,et al.  Treatment-Related Upper Limb Morbidity 1 Year after Sentinel Lymph Node Biopsy or Axillary Lymph Node Dissection for Stage I or II Breast Cancer , 2004, Annals of Surgical Oncology.

[11]  P. F. Short,et al.  Battery-powered health insurance? Stability in coverage of the uninsured. , 2003, Health affairs.

[12]  Rebecca Ottesen,et al.  Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. , 2003, Journal of the National Cancer Institute.

[13]  C. Bradley,et al.  Late Stage Cancers in a Medicaid-insured Population , 2003, Medical care.

[14]  J. Donohue,et al.  Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. , 2003, Archives of surgery.

[15]  S. Edge,et al.  Patient and provider characteristics that affect the use of axillary dissection in older women with Stage I–II breast carcinoma , 2002, Cancer.

[16]  J. Heimbach,et al.  Breast conservation therapy in affiliated county, university, and private hospitals. , 1999, American journal of surgery.

[17]  J. Zhang,et al.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. , 1998, JAMA.

[18]  C. McNeil Sentinel node biopsy: studies should bring needed data. , 1998, Journal of the National Cancer Institute.

[19]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[20]  C. Ko,et al.  Beyond the Clinical Trials: How Often Is Sentinel Lymph Node Dissection Performed for Breast Cancer? , 2004, Annals of Surgical Oncology.

[21]  M. Walker,et al.  Patterns of Recurrence After Sentinel Lymph Node Biopsy for Breast Cancer , 2003, Annals of Surgical Oncology.

[22]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.